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ulmonary hypertension (PH) is a condition that 
not only causes many problems for those 
suffering from it, but also can exacerbate and 
complicate many other diseases. PH can be 
responsible for mortality in many patients.  
  Tackling PH is not exclusively related to the field 
of cardiovascular diseases. Many other diseases in 
other fields of medicine may interfere with PH. 
Pulmonary diseases, renal, hepatic, collagen vascular 
disease, infectious and hematologic disease may be 
related with PH. In patients suffering from 
aforementioned diseases, PH can exacerbate the 
primary disorder and even cause mortality. Pregnant 
women afflicted with PH have a 30-50% mortality 
rate.1 Newborns and children with pulmonary or 
cardiovascular disorders can be later afflicted by PH. 
PH drastically increases the risk in surgeries and in 
anesthesia and can be the cause of mortalities2 or 
deteriorated outcomes in patients after surgery.3  
  According to the latest guidelines,4 there are 5 
categories of PH (Table 1): 
1- Pulmonary arterial hypertension 
2- Pulmonary venous hypertension (previously 
named pulmonary hypertension due to left heart 
disease) 
3- Pulmonary hypertension associated with 
hypoxemic lung disease 
4- Pulmonary hypertension caused by chronic 
thromboembolic disease 
5- Pulmonary hypertension from conditions with 
uncertain mechanisms 
  For a long time, the science of medicine had no 
remedy for PH and physicians could only stand by 
and watch PH patients die. 
  After some time, factors which complicate PH 
are known and it has been shown that controlling 
these factors is helpful. Patients are advised, for 
instance, to refrain from heavy exertion, to avoid 
pregnancy, and to be vaccinated against the flu and 
pneumococcal infections. PH patients’ life 
expectancy has increased dramatically as a result of 
this newly acquired knowledge. 
 
Table 1. Classification of pulmonary hypertension 
Category 1: Pulmonary Arterial Hypertension 
Idiopathic (IPAH) 
Sporadic 
Familial 
From exposure to drugs or toxins 
From exposure to HIV infection 
Persistent pulmonary hypertension of the newborn 
Associated with other active conditions: 
Congenital systemic to pulmonary shunts 
Collagen vascular disease 
Portal hypertension 
Pulmonary capillary hemangiomatosis (PCH) 
Category 2: Pulmonary Venous Hypertension 
Left-sided atrial or ventricular heart disease 
Left-sided valvular heart disease 
Pulmonary venous obstruction 
Pulmonary veno-occlusive disease (PVOD) 
Category 3: Pulmonary Hypertension Associated 
with Hypoxemic Lung Disease 
Chronic obstructive lung disease 
Interstitial lung disease 
Sleep-disordered breathing 
Alveolar hypoventilation disorders 
Chronic exposure to high altitude 
Developmental abnormalities 
Category 4: Pulmonary Hypertension Caused by 
Chronic Thromboembolic Disease 
Chronic pulmonary thromboembolism 
Nonthrombotic pulmonary embolism (tumor, foreign 
material) 
Category 5: Pulmonary Hypertension from 
Conditions with Uncertain Mechanisms 
 
Sarcoidosis 
Chronic anemia 
Schistosomiasis 
Histiocytosis X 
Lymphangiomatosis 
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  As PH was becoming better known, symptomatic 
cures came to patients’ help. Diuretic drugs were used 
to control edema and anticoagulants were used to put 
thromboembolic attacks in check.  
  Then, it was time for revolution in PH 
management. With the emergence of advanced PH 
treatment, science of medicine became able to 
seriously deal with PH. 
  This new strategy was showed to be able to 
prevent mortality in PH patients (Figure 1).5  
  Prostacyclin showed that it is possible to enhance 
PH patients’ chance of survival. Phosphodiesterase 
inhibitor drugs, which were used for treating 
impotency for a long time, were demonstrated to be 
effective for reducing pulmonary pressure. 
 Eventually,  endothelin  receptors were targeted. 
By the advent of endothelin receptor blockers such as 
Bosentan, physicians’ chances of helping PH patients 
were further improved. 
  Today, with advanced PH treatment, PH is not 
counted as before and the science of medicine as a 
failed discipline. 
  It is important not to forget PH in patients, 
especially ill patients or intractable to traditional 
treatment, in surgery wards or obstetric, pediatric, 
internal medicine, ICU or CCU wards of hospitals. 
  By timely diagnosis, it will be possible to control 
PH patients in an effective way and to enhance their 
chance of survival.  
  So, it is time now to pay more attention to PH. 
Don’t ignore it any longer; it’s time to deal with it. 
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Figure 1.  Efficacy of advanced pulmonary hypertension  treatment. 
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